The cost effectiveness of treating paediatric cancer in low-income and middle-income countries: A case-study approach using acute lymphocytic leukaemia in Brazil and Burkitt lymphoma in Malawi

Nickhill Bhakta, Alexandra L.C. Martiniuk, Sumit Gupta, Scott Howard

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Approximately 90% of children with cancer reside in low-income and middle-income countries (LMIC) where healthcare resources are scarce and allocation decisions difficult. The cost effectiveness of treating childhood cancers in these settings is unknown. The objective of the present work was to determine cost-effectiveness thresholds for common paediatric cancers using acute lymphoblastic leukaemia (ALL) in Brazil and Burkitt lymphoma (BL) in Malawi as examples. Disability-adjusted life years (DALYs) prevented by treatment were compared to the gross domestic product (GDP) per capita of each country to define cost-effectiveness thresholds using WHO-CHOICE ('CHOosing Interventions that are Cost-Effective') guidelines. The case examples were selected due to the data available and because ALL and BL both have the potential to yield significant health gains at a low cost per patient treated. The key findings were as follows: the 3:1 cost/DALY prevented to GDP/capita ratio for ALL in Brazil was US$771 225; expenditures below this threshold were cost effective. Costs below US$257 075 (1:1 ratio) were considered very cost effective. Analogous thresholds for BL in Malawi were US$42 729 and US$14 243. Actual costs were far less. In Brazil, US$16 700 was spent to treat each patient while in Malawi total drug costs were less than US$50 per child. In summary, treatment of certain paediatric cancers in LMIC is very cost effective. Future research should evaluate actual treatment and infrastructure expenditures to help guide policymakers.

Original languageEnglish (US)
Pages (from-to)155-160
Number of pages6
JournalArchives of Disease in Childhood
Volume98
Issue number2
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Fingerprint

Malawi
Burkitt Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cost-Benefit Analysis
Brazil
Pediatrics
Costs and Cost Analysis
Neoplasms
Gross Domestic Product
Quality-Adjusted Life Years
Health Expenditures
Drug Costs
Resource Allocation
Therapeutics
Guidelines
Delivery of Health Care
Health

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{41a502f94a1d4b88aaecc0ce93caffdb,
title = "The cost effectiveness of treating paediatric cancer in low-income and middle-income countries: A case-study approach using acute lymphocytic leukaemia in Brazil and Burkitt lymphoma in Malawi",
abstract = "Approximately 90{\%} of children with cancer reside in low-income and middle-income countries (LMIC) where healthcare resources are scarce and allocation decisions difficult. The cost effectiveness of treating childhood cancers in these settings is unknown. The objective of the present work was to determine cost-effectiveness thresholds for common paediatric cancers using acute lymphoblastic leukaemia (ALL) in Brazil and Burkitt lymphoma (BL) in Malawi as examples. Disability-adjusted life years (DALYs) prevented by treatment were compared to the gross domestic product (GDP) per capita of each country to define cost-effectiveness thresholds using WHO-CHOICE ('CHOosing Interventions that are Cost-Effective') guidelines. The case examples were selected due to the data available and because ALL and BL both have the potential to yield significant health gains at a low cost per patient treated. The key findings were as follows: the 3:1 cost/DALY prevented to GDP/capita ratio for ALL in Brazil was US$771 225; expenditures below this threshold were cost effective. Costs below US$257 075 (1:1 ratio) were considered very cost effective. Analogous thresholds for BL in Malawi were US$42 729 and US$14 243. Actual costs were far less. In Brazil, US$16 700 was spent to treat each patient while in Malawi total drug costs were less than US$50 per child. In summary, treatment of certain paediatric cancers in LMIC is very cost effective. Future research should evaluate actual treatment and infrastructure expenditures to help guide policymakers.",
author = "Nickhill Bhakta and Martiniuk, {Alexandra L.C.} and Sumit Gupta and Scott Howard",
year = "2013",
month = "2",
day = "1",
doi = "10.1136/archdischild-2011-301419",
language = "English (US)",
volume = "98",
pages = "155--160",
journal = "Archives of Disease in Childhood",
issn = "0003-9888",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - The cost effectiveness of treating paediatric cancer in low-income and middle-income countries

T2 - A case-study approach using acute lymphocytic leukaemia in Brazil and Burkitt lymphoma in Malawi

AU - Bhakta, Nickhill

AU - Martiniuk, Alexandra L.C.

AU - Gupta, Sumit

AU - Howard, Scott

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Approximately 90% of children with cancer reside in low-income and middle-income countries (LMIC) where healthcare resources are scarce and allocation decisions difficult. The cost effectiveness of treating childhood cancers in these settings is unknown. The objective of the present work was to determine cost-effectiveness thresholds for common paediatric cancers using acute lymphoblastic leukaemia (ALL) in Brazil and Burkitt lymphoma (BL) in Malawi as examples. Disability-adjusted life years (DALYs) prevented by treatment were compared to the gross domestic product (GDP) per capita of each country to define cost-effectiveness thresholds using WHO-CHOICE ('CHOosing Interventions that are Cost-Effective') guidelines. The case examples were selected due to the data available and because ALL and BL both have the potential to yield significant health gains at a low cost per patient treated. The key findings were as follows: the 3:1 cost/DALY prevented to GDP/capita ratio for ALL in Brazil was US$771 225; expenditures below this threshold were cost effective. Costs below US$257 075 (1:1 ratio) were considered very cost effective. Analogous thresholds for BL in Malawi were US$42 729 and US$14 243. Actual costs were far less. In Brazil, US$16 700 was spent to treat each patient while in Malawi total drug costs were less than US$50 per child. In summary, treatment of certain paediatric cancers in LMIC is very cost effective. Future research should evaluate actual treatment and infrastructure expenditures to help guide policymakers.

AB - Approximately 90% of children with cancer reside in low-income and middle-income countries (LMIC) where healthcare resources are scarce and allocation decisions difficult. The cost effectiveness of treating childhood cancers in these settings is unknown. The objective of the present work was to determine cost-effectiveness thresholds for common paediatric cancers using acute lymphoblastic leukaemia (ALL) in Brazil and Burkitt lymphoma (BL) in Malawi as examples. Disability-adjusted life years (DALYs) prevented by treatment were compared to the gross domestic product (GDP) per capita of each country to define cost-effectiveness thresholds using WHO-CHOICE ('CHOosing Interventions that are Cost-Effective') guidelines. The case examples were selected due to the data available and because ALL and BL both have the potential to yield significant health gains at a low cost per patient treated. The key findings were as follows: the 3:1 cost/DALY prevented to GDP/capita ratio for ALL in Brazil was US$771 225; expenditures below this threshold were cost effective. Costs below US$257 075 (1:1 ratio) were considered very cost effective. Analogous thresholds for BL in Malawi were US$42 729 and US$14 243. Actual costs were far less. In Brazil, US$16 700 was spent to treat each patient while in Malawi total drug costs were less than US$50 per child. In summary, treatment of certain paediatric cancers in LMIC is very cost effective. Future research should evaluate actual treatment and infrastructure expenditures to help guide policymakers.

UR - http://www.scopus.com/inward/record.url?scp=84872674486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872674486&partnerID=8YFLogxK

U2 - 10.1136/archdischild-2011-301419

DO - 10.1136/archdischild-2011-301419

M3 - Article

C2 - 23201550

AN - SCOPUS:84872674486

VL - 98

SP - 155

EP - 160

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

SN - 0003-9888

IS - 2

ER -